New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Rethinking how cancer cells evade targeted therapy

Rethinking how cancer cells evade targeted therapy

byUniversity of California, San FranciscoA single-cell RNA atlas of human glioblastoma through recurrence.a, An overview of genomics studies on paired longitudinal GBM specimens.b, A
Oncology January 22,2024
Rethinking how cancer cells evade targeted therapy

Rethinking how cancer cells evade targeted therapy

byUniversity of California, San FranciscoA single-cell RNA atlas of human glioblastoma through recurrence.a, An overview of genomics studies on paired longitudinal GBM specimens.b, A
Oncology January 22,2024
Prognosis of multiple myeloma has improved since 2000

Prognosis of multiple myeloma has improved since 2000

by Elana GotkineFor patients with multiple myeloma (MM), there has been an improvement in prognosis since 2000, but mortality still remains elevated, according to a study published online April 6 in&n
Oncology January 22,2024
Prognosis of multiple myeloma has improved since 2000

Prognosis of multiple myeloma has improved since 2000

by Elana GotkineFor patients with multiple myeloma (MM), there has been an improvement in prognosis since 2000, but mortality still remains elevated, according to a study published online April 6 in&n
Oncology January 22,2024
Minimal residual disease negativity predicts time to next treatment in multiple myeloma

Minimal residual disease negativity predicts time to next treatment in multiple myeloma

by Elana GotkineFor patients with multiple myeloma (MM), minimal residual disease (MRD) negativity determined using next-generation sequencing (NGS) is predictive of longer time to next treatment (TTN
Oncology January 22,2024
Minimal residual disease negativity predicts time to next treatment in multiple myeloma

Minimal residual disease negativity predicts time to next treatment in multiple myeloma

by Elana GotkineFor patients with multiple myeloma (MM), minimal residual disease (MRD) negativity determined using next-generation sequencing (NGS) is predictive of longer time to next treatment (TTN
Oncology January 22,2024
Treatment decisions in new era of individualized therapy for metastatic hormone-sensitive prostate cancer

Treatment decisions in new era of individualized therapy for metastatic hormone-sensitive prostate cancer

byDana-Farber Cancer InstituteProstate cancer cells. Credit: NIH Image GalleryOncologists have traditionally prescribed androgen deprivation therapy (ADT) alone for patients with metastatic horm
Oncology January 22,2024
Treatment decisions in new era of individualized therapy for metastatic hormone-sensitive prostate cancer

Treatment decisions in new era of individualized therapy for metastatic hormone-sensitive prostate cancer

byDana-Farber Cancer InstituteProstate cancer cells. Credit: NIH Image GalleryOncologists have traditionally prescribed androgen deprivation therapy (ADT) alone for patients with metastatic horm
Oncology January 22,2024
Tumor microbiome linked to immunotherapy success in sarcoma patients

Tumor microbiome linked to immunotherapy success in sarcoma patients

by Stephanie Winn,UC DavisSoft tissue sarcomas intratumoral microbiome at diagnosis may link with prognosis. (A) Representative gross examination of extremity synovial sarcoma specimen; asterisk
Oncology January 22,2024
Tumor microbiome linked to immunotherapy success in sarcoma patients

Tumor microbiome linked to immunotherapy success in sarcoma patients

by Stephanie Winn,UC DavisSoft tissue sarcomas intratumoral microbiome at diagnosis may link with prognosis. (A) Representative gross examination of extremity synovial sarcoma specimen; asterisk
Oncology January 22,2024
How metastatic cancer causes leaky blood vessels

How metastatic cancer causes leaky blood vessels

byAmerican Institute of PhysicsImmunofluorescence images showing the effects of contactless paracrine signaling interactions (left) or physical contact (right) in micropatterned endothelial cell
Oncology January 22,2024
How metastatic cancer causes leaky blood vessels

How metastatic cancer causes leaky blood vessels

byAmerican Institute of PhysicsImmunofluorescence images showing the effects of contactless paracrine signaling interactions (left) or physical contact (right) in micropatterned endothelial cell
Oncology January 22,2024
Blocking a key immune protein improves radiation therapy for cancer

Blocking a key immune protein improves radiation therapy for cancer

byUniversity of ChicagoCredit: Unsplash/CC0 Public DomainUp to 60% of cancer patients receive radiation therapy, but it doesn't always work. Failure of these treatments results from tumor re
Oncology January 22,2024
Blocking a key immune protein improves radiation therapy for cancer

Blocking a key immune protein improves radiation therapy for cancer

byUniversity of ChicagoCredit: Unsplash/CC0 Public DomainUp to 60% of cancer patients receive radiation therapy, but it doesn't always work. Failure of these treatments results from tumor re
Oncology January 22,2024
Most women diagnosed with early breast cancer can expect to become long-term survivors, say experts

Most women diagnosed with early breast cancer can expect to become long-term survivors, say experts

byBritish Medical JournalCredit:BMJ(2023). DOI: 10.1136/bmj-2022-074684Most women diagnosed with early stage breast cancer today can expect to become long-term cancer survivors, find
Oncology January 22,2024
Most women diagnosed with early breast cancer can expect to become long-term survivors, say experts

Most women diagnosed with early breast cancer can expect to become long-term survivors, say experts

byBritish Medical JournalCredit:BMJ(2023). DOI: 10.1136/bmj-2022-074684Most women diagnosed with early stage breast cancer today can expect to become long-term cancer survivors, find
Oncology January 22,2024
Experts call for adequate tumor-free margins in breast cancer surgery to reduce recurrence and improve survival

Experts call for adequate tumor-free margins in breast cancer surgery to reduce recurrence and improve survival

byBritish Medical JournalCredit: Pixabay/CC0 Public DomainSurgeons should aim to remove at least a 1-mm width rim (margin) of healthy tissue around a breast tumor to reduce the risk of cancer re
Oncology January 22,2024
Experts call for adequate tumor-free margins in breast cancer surgery to reduce recurrence and improve survival

Experts call for adequate tumor-free margins in breast cancer surgery to reduce recurrence and improve survival

byBritish Medical JournalCredit: Pixabay/CC0 Public DomainSurgeons should aim to remove at least a 1-mm width rim (margin) of healthy tissue around a breast tumor to reduce the risk of cancer re
Oncology January 22,2024
How the tumor microenvironment stimulates pancreatic cancer growth and progression

How the tumor microenvironment stimulates pancreatic cancer growth and progression

by Nancy Fliesler,Children's Hospital BostonMyeloid-specific deletion of LRP1 inhibits tumor growth by preventing the repression of Tsp-1. A Plot of percentage of LRP1 + multiple myeloid and
Oncology January 22,2024
How the tumor microenvironment stimulates pancreatic cancer growth and progression

How the tumor microenvironment stimulates pancreatic cancer growth and progression

by Nancy Fliesler,Children's Hospital BostonMyeloid-specific deletion of LRP1 inhibits tumor growth by preventing the repression of Tsp-1. A Plot of percentage of LRP1 + multiple myeloid and
Oncology January 22,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com